SEC Form 4 · accession 0001209191-19-014162
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Barth
Officer — Chief Medical Officer
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2019 | M | 26,270 | $2.29 | A | 156,037 | D | |
| Common StockF2 | Feb 25, 2019 | S | 26,270 | $12.5162 | D | 129,767 | D | |
| Common Stock | Feb 25, 2019 | M | 43,730 | $2.94 | A | 173,497 | D | |
| Common StockF2 | Feb 25, 2019 | S | 43,730 | $12.5162 | D | 129,767 | D | |
| Common Stock | holding | — | — | — | 31 | I | by Daughter |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $2.29 | Feb 25, 2019 | M | 26,270 | D | — | Mar 3, 2024 | Common Stock | 26,270 | 68,730 | D |
| Stock Options (right to buy)F3 | $2.94 | Feb 25, 2019 | M | 43,730 | D | — | Jun 26, 2024 | Common Stock | 43,730 | 6,270 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2018.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3All of the options were fully vested and exercisable as of February 25, 2019.